Which statement is true regarding HIV-infected parturients?

Which statement is true regarding HIV-infected parturients?

• A. Central neurologic blockade increases the chance of neurologic complications
• B. Ninety percent of newborns of untreated HIV seropositive mothers become infected in-utero, during vaginal delivery or with breastfeeding
• C. The pharmacologic effects of benzodiazepines are prolonged in patients taking protease inhibitors
• D. Epidural blood patch is contraindicated for the treatment of post-dural puncture headaches

Answer: (C)

The main idea here is how HIV therapy can interact with anesthesia drugs. Protease inhibitors used to treat HIV are strong inhibitors of the liver enzyme CYP3A4. Many benzodiazepines—such as midazolam, triazolam, and alprazolam—are broken down by that same enzyme. When a patient is taking protease inhibitors, the metabolism of these benzodiazepines slows down, so the drugs stay in the body longer and their effects are prolonged. This can mean longer sedation, greater anxiolysis, and a higher risk of respiratory depression, which is especially important to manage in parturients and during labor or postpartum care. Clinically, this means we may need to use lower benzodiazepine doses, choose agents with less reliance on CYP3A4, or monitor closely for oversedation in HIV-infected patients on protease inhibitors. The other statements don’t fit as well. Neuraxial blockade is not inherently more risky just because a parturient has HIV, unless there are other contraindications; perinatal transmission rates without treatment are far lower than 90% with contemporary care, and with antiretroviral prophylaxis the risk drops markedly; and an epidural blood patch is a standard treatment for post-dural puncture headaches, not a contraindication.

The main idea here is how HIV therapy can interact with anesthesia drugs. Protease inhibitors used to treat HIV are strong inhibitors of the liver enzyme CYP3A4. Many benzodiazepines—such as midazolam, triazolam, and alprazolam—are broken down by that same enzyme. When a patient is taking protease inhibitors, the metabolism of these benzodiazepines slows down, so the drugs stay in the body longer and their effects are prolonged. This can mean longer sedation, greater anxiolysis, and a higher risk of respiratory depression, which is especially important to manage in parturients and during labor or postpartum care. Clinically, this means we may need to use lower benzodiazepine doses, choose agents with less reliance on CYP3A4, or monitor closely for oversedation in HIV-infected patients on protease inhibitors.

The other statements don’t fit as well. Neuraxial blockade is not inherently more risky just because a parturient has HIV, unless there are other contraindications; perinatal transmission rates without treatment are far lower than 90% with contemporary care, and with antiretroviral prophylaxis the risk drops markedly; and an epidural blood patch is a standard treatment for post-dural puncture headaches, not a contraindication.